Reviewer's report

Title: Bevacizumab plus FOLFIRI or FOLFOX as third and further line treatment in metastatic colorectal cancer patients: a retrospective study.

Version: 2 Date: 18 March 2009

Reviewer: Peter Martus

Reviewer's report:

Short statement for statistical analysis:

This is an observational, retrospective study without control group, thus the level of evidence is very low and the authors have to remove the term "efficacy" from the manuscript.

You cannot prove efficacy with this study design.

The methods of testing (Fisher's Exact test, Kaplan Meier) and the definitions of OS and PFS are correct. The authors should use the Landmark method for their analysis of survival by response. The conclusion - need for a randomized trial - is sound.